CN117323337A - 山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用 - Google Patents
山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用 Download PDFInfo
- Publication number
- CN117323337A CN117323337A CN202311429532.2A CN202311429532A CN117323337A CN 117323337 A CN117323337 A CN 117323337A CN 202311429532 A CN202311429532 A CN 202311429532A CN 117323337 A CN117323337 A CN 117323337A
- Authority
- CN
- China
- Prior art keywords
- liver
- thh
- begonin
- medicine
- alcoholic fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 56
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 210000004185 liver Anatomy 0.000 claims abstract description 31
- 210000002966 serum Anatomy 0.000 claims abstract description 22
- 230000002440 hepatic effect Effects 0.000 claims abstract description 14
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 14
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 230000003908 liver function Effects 0.000 claims abstract description 12
- 238000011084 recovery Methods 0.000 claims abstract description 11
- 230000006378 damage Effects 0.000 claims abstract description 10
- 230000001737 promoting effect Effects 0.000 claims abstract description 10
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 7
- 230000003647 oxidation Effects 0.000 claims abstract description 7
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 7
- 230000009471 action Effects 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims description 19
- 239000003826 tablet Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 108010023302 HDL Cholesterol Proteins 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 10
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 108010002352 Interleukin-1 Proteins 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 7
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 206010067125 Liver injury Diseases 0.000 abstract description 4
- 231100000753 hepatic injury Toxicity 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000000903 blocking effect Effects 0.000 abstract description 3
- 230000001590 oxidative effect Effects 0.000 abstract description 3
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 40
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- 241000218993 Begonia Species 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229940118019 malondialdehyde Drugs 0.000 description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 description 8
- 241000545405 Tripterygium Species 0.000 description 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 230000007863 steatosis Effects 0.000 description 6
- 241001197778 Tripterygium hypoglaucum Species 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 102000004125 Interleukin-1alpha Human genes 0.000 description 3
- 108010082786 Interleukin-1alpha Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000007730 Akt signaling Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000208365 Celastraceae Species 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000220225 Malus Species 0.000 description 2
- 241001481296 Malus spectabilis Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 241000830536 Tripterygium wilfordii Species 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000003090 exacerbative effect Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000015398 thunder god vine Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 102100034009 Glutamate dehydrogenase 1, mitochondrial Human genes 0.000 description 1
- 101710122201 Glutamate dehydrogenase 2 Proteins 0.000 description 1
- 102100022314 Glutamate dehydrogenase 2, mitochondrial Human genes 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 101000870042 Homo sapiens Glutamate dehydrogenase 1, mitochondrial Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101150009046 Tnfrsf1a gene Proteins 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 241000545403 Tripterygium regelii Species 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000021069 high fat-high sugar diet Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及药物制备技术领域,具体涉及山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用,山海棠素对肝小叶和肝索结构破坏的恢复具有促进恢复作用;促进恢复作用具体包括:血清肝功能(AST和ALT)、血脂和肝脂(HDL‑C、LDL‑C、TG和TC)、肝脏和血清炎性因子(IL‑1、IL‑6和TNF‑α)水平的提高,SOD、MDA、GSH、CAT等相关的氧化和抗氧化能力的提高。山海棠素具有抗炎、促进肝小叶和肝索结构恢复、调节氧化状态和血脂的作用。对于改善肝功能、抑制炎症反应、减轻肝脏损伤以及阻断非酒精性脂肪性肝病的进展具有重要意义,有效指导非酒精性脂肪性肝病药物的研发与制备。
Description
技术领域
本发明涉及药物制备技术领域,具体涉及山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用。
背景技术
非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是指排除其他的肝脏脂肪变性疾病,包括过度饮酒、使用脂肪变性药物或遗传性疾病等条件后,通过影像学或组织学诊断存在肝脏内甘油三酯异常聚集、炎症浸润为主要特征的疾病。NAFLD疾病谱包括从没有炎症的单纯性脂肪肝(NAFL),到非酒精性脂肪性肝炎(NASH)、肝硬化(NAFC)和肝细胞癌(HCC)一系列进展过程。随着国家工业化程度的提高,以及人们生活方式和饮食结构的改变,NAFLD的患病率不断攀升,是日益增长的形成肝硬化和肝癌的原因之一,目前已成为全球公认的第一大慢性肝病。NAFLD在发展中国家的患病率呈现后来居上的趋势,约为25%,而我国患病率早已超过了32.9%。由此可见,NAFLD严重威胁着人类的健康,因此深入研究NAFLD的发病机制,寻求有效的治疗药物,是必不可少的。
NAFLD其发病机制至今尚未完全阐明。目前最广泛认可的发病机制是由Day和Jame提出的“二次打击”学说,“第一次打击”是指以胰岛素抵抗(IR)为前提导致肝细胞脂肪变性。第二次打击是在初次打击的基础上,以脂质过氧化、氧化应激和线粒体损伤导致肝细胞发生炎症、变性、坏死和纤维化。近年来,随着分子生物学的发展,对疾病产生的分子机制的研究也更加深入,越来越多的研究者们发现,NASH是多重伤害共同作用的结果,包括肝脂肪堆积、营养因素、肠道微生物群和表观遗传因素等。近年来的大量研究表明Toll样受体4(toll likereceptor4,TLR4)/核因子-κB(NF-κB)通路在NASH发生发展中起着重要作用,成为了现阶段研究的热点。已有研究证明中药可通过阻断TLR4/NF-κB通路来抑制肝脏炎症反应,在改善NASH中起重要作用。TNFα也被认为是NAFLD的主要致病因子。TNFα介导的肝损伤主要通过TNFα-受体-1(TNFR1)信号通路发生。
昆明山海棠[Tripterygium Hypoglaucum(Levl.)Hutch,THH]为卫矛科雷公藤属植物,生长于向阳山坡、路边或灌木丛中。我国THH资源丰富,主产于云南省。通常以根和皮作为药用,主治风湿性关节炎、类风湿性关节炎、慢性肾炎、各种皮肤病、跌打损伤、无名肿毒等。THH化学成分非常复杂,包括生物碱、萜类、苷类、糖类、有机酸、多糖等多种化学成分,其中萜类和生物碱类是它们的主要活性成分。山海棠素从昆明山海棠根皮中分离得到,得率约0.0005%。熔点232-233℃。质谱测得分子量312。根据质谱和元素分析数据分子式为C20H2403。然而目前,对于雷公藤药材的植物来源存在一定争议,在《中国植物志》(中文版)中卫矛科雷公藤属有3个植物来源,分别为雷公藤(Trip terygium wilfordii Hook)、昆明山海棠[Tripterygium.hypoglaucum(Levl.)]和东北雷公藤(T.regellii Sprague etTakeda)。
尽管THH在临床上过量或长期暴露且治疗窗口狭窄。但该属植物在治疗银屑病、风湿病(RA)、系统性红斑狼疮(SLE)等自身性免疫疾病方面,具有良好疗效,因此,受到了广泛的关注,国内外学者对其生药学、化学成分、药理作用、临床应用等方面行了较多的研究和报道,对昆明山海棠提取物中山海棠素在小鼠体内的代谢物进行系统分析后发现山海棠素在小鼠体内经过内部水解、氧化、甲基化、氧化后甲基化、三氧化等多种转化方式,形成系列相关代谢产物共26种。近年的研究表明,THH还具有雄性和雌性抗生育作用、诱导细胞凋亡作用、抗肿瘤活性及体外抗HSV活性。并且昆明山海棠具有良好的抗炎免疫抑制活性,且昆明山海棠毒性小于雷公藤,且具备较强的抗炎免疫抑制活性,具有良好的开发利用价值;
THH对抗类风湿性关节炎RA的机制与31条信号通路有关,关键机制与通过灭活TNF和NF-κB信号通路抑制炎症反应有关。THH能显著抑制炎性因子IL-1α、IL-1β和MMP3的释放,同时IL-4和IL-10的表达水平和Treg细胞的含量均有显著提高,采用靶向代谢组学法验证THH给药14d后L-谷氨酸和谷氨酰胺发生显著变化,其许多活性成分可与谷氨酸脱氢酶2(GLUD2)成功对接。通过对THH-RA、THH-SLE和THH-ADR网络的富集分析结果表明,癌症、乙型肝炎、类风湿性关节炎和PI3K-Akt信号通路可能参与THH治疗RA和SLE。此外,THH诱导的ADRs机制与病毒癌变、PI3K-Akt信号通路等有关。然而,THH的这些活性成分与关键靶标(包括STAT53,VEGFA,TP9和MMP)发挥了卓越的结合活性,通过分子对接模拟观察到这些靶标具有协同功效和毒性。THH具有抗炎、抗肿瘤,免疫抑制的生物活性.在临床治疗中常用于治疗自身免疫性疾病,并且已有良好的临床疗效。Zhou X等人使用健康雄性C57BL/6小鼠对CIA小鼠进行建模,通过管饲法使小鼠接受THH 420mg/kg/天或等量的生理盐水(NS)20天。结果表明,用THH治疗后,CIA小鼠关节肿胀和破坏减少,足部尺寸和关节炎指数降低。THH处理组TNF-α、IFN-γ和IL-17A的mRNA和蛋白水平低于NS组(P<0.05)。综上,THH可能是通过抑制NF-κB-STAT3-IL-17途径降低关节组织和血清中相关炎性细胞因子的表达水平。
昆明山海棠也早已经被纳入临床中使用,该中药片剂收载于2005年版《中华人民共和国药典》,并且其有效成分山海棠素广泛应用于临床上,因宁片是南方医科大学南方医院医药专家共同拟定的治疗阴虚阳亢型甲亢伴肝损害的临床经验处方,因宁片主要由黄芪、昆明山海棠、莪术、五味子等9味中药材组方而成具有益气养阴、化痰祛瘀、散结消瘿之功效。本发明中所利用的昆明山海棠的活性成分的得到了进一步的提纯,有效成分将会被最大程度的保存,其作为单体成分,具有比复方更好的吸收力、药效更加稳定也具有更少的不良反应。没有复方那样用药繁琐,患者的依从性会更高,可以起到更好的疗效。
研究人员从THH中分离得到的化合物进行了体外抗肿瘤活性与抗炎活性评价。采用5种人肿瘤细胞模型,为A549(肺癌细胞)、DU145(前列腺癌细胞)、KB(口腔表皮样癌细胞)和MDA-MB-231(乳腺癌细胞)进行抗肿瘤活性试验,使用临床抗肿瘤药物紫杉醇作为阳性对照品。试验结果提示,THH对多种肿瘤细胞具有显著的抗肿瘤活性萜类成分是昆明山海棠的主要活性成分,其它类型成分也起到一定的协同作用。
基于以上研究,能够充分证明THH在抗炎、抗细胞凋亡、抗癌症的作用。但少有研究证明THH能够与NAFLD或NASH相关,截止日前关于THH与NAFLD或NASH的治疗作用在国内外均没有报告。
由于目前在NAFLD的治疗上并无特效药,对于NAFLD治疗主要采取一般治疗和药物治疗并行的方式,一般治疗方式包括适当休息、合理饮食、适量运动等,药物治疗主要涉及抗氧化剂、肝细胞保护剂、胰岛素增敏剂、调脂药、减肥药等,但这些药物既缺乏较理想的疗效,又都具有较多的副作用,导致临床用药有一定局限性。但生活方式的改变(如适当控制体质量)和代谢危险因素(如糖尿病和高脂血症)的改善仍然是治疗NAFLD的基础。因此,针对发病机制的多靶点联合治疗或许是NAFLD治疗的研究新方向。本次作者应用THH治疗NAFLD,发现在实验中THH可以明显的降低大鼠炎症反应,明显减轻了NAFLD大鼠的炎性浸润程度和脂肪变性程度,对氧化应激指标也有轻微的改善,具有多靶点治疗作用。
发明内容
本发明的目的在于提供山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用,
为实现上述技术目的,达到上述技术效果,本发明是通过以下技术方案实现:
山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用。
进一步的,山海棠素对肝小叶和肝索结构破坏的恢复具有促进恢复作用。
进一步的,促进恢复作用具体包括:血清肝功能(AST和ALT)、血脂和肝脂(HDL-C、LDL-C、TG和TC)、肝脏和血清炎性因子(IL-1、IL-6和TNF-α)水平的提高,SOD、MDA、GSH、CAT等相关的氧化和抗氧化能力的提高。
进一步的,所述药物包含有效剂量的山海棠素THH和制药学上可接受的药物辅剂。
进一步的,所述有效剂量为0-420mM。
进一步的,所述药物为为内用药物,包括但不限于胶囊剂、丸剂、粉剂、片剂、粒剂、口服液或注射液。
本发明的有益效果:
抗炎作用:非酒精性脂肪性肝病(NAFLD)的病理过程中,炎症反应是一个重要的环节。炎症反应的激活导致肝脏的组织损伤和纤维化,进一步加重疾病进展。山海棠素通过抑制炎性因子的释放,如IL-1、IL-6和TNF-α,可以有效抑制炎症反应的发生和发展。
促进肝小叶和肝索结构恢复:非酒精性脂肪性肝病的进展过程中,肝小叶和肝索结构受到破坏,而其恢复对于改善肝功能和抑制疾病进展至关重要。山海棠素可以促进肝小叶和肝索结构的重建,减轻脂肪变性和炎症浸润程度,从而有助于恢复正常肝脏结构。
调节氧化状态:非酒精性脂肪性肝病的发展与氧化应激密切相关。氧化应激导致肝细胞内氧自由基的产生增加,导致细胞膜的脂质过氧化和其他损伤,进一步加剧肝脏的炎症和损伤。山海棠素可以提高抗氧化酶如SOD、GSH和CAT的活性,同时降低氧化应激标志物MDA的水平,从而改善肝细胞的氧化状态,减轻氧化应激对肝脏的损伤。
调节血脂代谢:非酒精性脂肪性肝病患者常伴随血脂代谢异常和肝脂堆积。山海棠素可以降低血清血脂水平,如LDL-C和TG,同时提高HDL-C水平。此外,山海棠素还能减少肝脂的沉积,减轻脂肪变性和肝纤维化的程度。
总的来说,山海棠素具有抗炎、促进肝小叶和肝索结构恢复、调节氧化状态和血脂的作用。对于改善肝功能、抑制炎症反应、减轻肝脏损伤以及阻断非酒精性脂肪性肝病的进展具有重要意义,有效指导非酒精性脂肪性肝病药物的研发与制备。
当然,实施本发明的任一产品并不一定需要同时达到以上所述的所有优点。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例描述所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是本发明THH治疗NAFLD大鼠后的大鼠肝脏病理学HE染色结果示意图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
实施例1
如本实施例所述的山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用。
在本实施例中,山海棠素对肝小叶和肝索结构破坏的恢复具有促进恢复作用。
在本实施例中,促进恢复作用具体包括:血清肝功能(AST和ALT)、血脂和肝脂(HDL-C、LDL-C、TG和TC)、肝脏和血清炎性因子(IL-1、IL-6和TNF-α)水平的提高,SOD、MDA、GSH、CAT等相关的氧化和抗氧化能力的提高。
在本实施例中,所述药物包含有效剂量的山海棠素THH和制药学上可接受的药物辅剂。
在本实施例中,所述有效剂量为0-420mM。
在本实施例中,所述药物为为内用药物,包括但不限于胶囊剂、丸剂、粉剂、片剂、粒剂、口服液或注射液。
实施例2
PHA治疗NAFLD大鼠后大鼠肝脏组织形态和病理学观察研究
实验中采用的实验动物为SD大鼠,大鼠均为雄性,体重为180-200g,由昆明医科大学实验动物中心提供,大鼠采用大笼12只,小笼6只隔离饲养,饲养为常规高脂高糖饮食饲料,自由饮食和饮水。
实验药品昆明山海棠[Tripterygium Hypoglaucum(Levl.)Hutch,THH]为上海联迈生物工程有限公司;高密度脂蛋白胆固醇(HDL-C)、低高密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)、谷丙转氨酶(ALT)和谷草转氨酶(AST)试剂盒;白细胞介素-1α(IL-1α)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)试剂盒;总超氧化物歧化酶(T-SOD)、丙二醛(MDA)及谷胱甘肽过氧化物酶(GSH-PX)等相关Elisa试剂盒购于Bio-Swamp公司。原位末端标记法(TUNEL)法检测试剂盒,德国Boehringer Mannheim公司提供。
48只大鼠随机分为空白对照(CON)组12只,模型对照(HFD)组l2只,THH低、高剂量组每组12只。CON组给予基础饲料喂养,HFD组、THH治疗组给予高脂高糖饲料喂养。喂养12w后,每组各取二只大鼠处死,收集肝脏HE染色检测肝脏病理学,收集血液检测肝功能,肝脏HE染色有明显脂肪空泡,同时肝功能指标AST和ALT明显升高判定为脂肪肝造模成功。证实模型建立成功后,造模成功后给予相应治疗,其中正常组和模型组给予2mL生理盐水灌胃治疗,THH两个剂量组分别给予THH210和420mg/kg/d灌胃治疗,治疗时将相应药物分散于2mL生理盐水中灌胃,治疗时间为8周。
收集肝脏组织,采用组织固定液固定24h-72h后,取出,脱水透明后,依次经石蜡包埋、切片、脱蜡、脱水、苏木精伊红染色,透明及中性树脂封片,完成后采用荧光倒置显微镜收集图像。从图1中可看出:正常组大鼠肝小叶和肝索清晰可见,没有任何脂肪变性、坏死以及组织增生;而模型组则出现明显的肝小叶和肝索结构破坏,出现大量的脂肪空泡,细胞核受到一定的挤压紧贴细胞膜;与模型组相比,各治疗组均有一定程度的好转。提示:THH治疗NAFLD大鼠可以改善大鼠肝脏病理学情况。
实施例3
HA治疗NAFLD大鼠后大鼠肝功能及脂代谢改善情况的研究
本实验中所采用的动物和实验药品和实施例2相同,AST、ALT、HDL-C、LDL-C、TG和TC等相关试剂盒购于Bio-Swamp公司。
实验中大鼠造模和治疗和实施例2中所采用的方法相同。
用相应试剂盒检测大鼠血清AST、ALT、HDL-C、LDL-C、TG和TC等6个指标。
与正常组相比,模型组血清AST和ALT,血清和肝脏HDL-C、LDL-C、TG、TC均明显升高,各治疗组相较于模型组上述指标均明显降低(AST:模型对照组158.26±10.01mmol/L,THH低剂量治疗组103.38±7.08mmol/L,THH高剂量治疗组97.21±7.14mmol/L,空白对照组83.28±8.94mmol/L;ALT:模型对照组39.14±6.61mmol/L,THH低剂量治疗组44.19±8.03mmol/L,THH高剂量治疗组41.56±7.31mmol/L,空白对照组39.14±6.61mmol/L;HDL-C:模型对照组1.83±0.31mmol/L,THH低剂量治疗组1.74±0.27mmol/L,THH高剂量治疗组1.70±0.19mmol/L;空白对照组1.09±0.17mmol/L;LDL-C:模型对照组0.97±0.8mmol/L,THH低剂量治疗组0.41±0.18mmol/L,THH高剂量治疗组0.41±0.07mmol/L,空白对照组0.36±0.02mmol;TG:模型对照组1.94±0.69mmol/L,THH低剂量治疗组1.73±0.25mmol/L,THH高剂量治疗组1.63±0.11mmol/L,空白对照组0.99±0.12mmol/L;TC:模型对照组2.72±0.25mmol/L,THH低剂量治疗组1.41±0.10mmol/L,THH高剂量治疗组1.42±0.07mmol/L,空白对照组2.31±0.06mmol/L。)(p<0.05),详见表1、2;表1和表2是本发明THH治疗NAFLD大鼠后的大鼠血清肝功能及脂代谢改善情况比较;
表1THH对NAFLD大鼠血清肝功能指标的影响
注:与正常组相比,*P<0.05;与模型组相比,**P<0.05。(下同)
表2 THH对NAFLD大鼠血清血脂指标的影响
实施例4
THH治疗NAFLD大鼠后大鼠血清中抗氧化能力含量的研究
本实验中所采用的动物和实验药品和实施例2相同,SOD、MDA、GSH、CAT等相关试剂盒购自南京生物工程研究所。
实验中大鼠造模和治疗和实施例2中所采用的方法相同。
用相应试剂盒检测大鼠血清SOD、MDA、GSH、CAT四个指标。
THH治疗组与模型组相比,得到了明显的改善,经检验治疗后四个指标P<0.05,提示:THH治疗NAFLD大鼠可以明显的提高大鼠抗氧化能力(SOD:模型对照组463.09±11.87U/mg,THH低剂量治疗组376.98±37.84U/mg,THH高剂量治疗组324.26±48.04U/mg,空白对照组299.36±57.61U/mg;MDA:模型对照组7.36±0.27nmol/mg,THH低剂量治疗组6.62±0.15nmol/mg,THH高剂量治疗组5.29±0.09nmol/mg,空白对照组5.08±0.13nmol/mg;GSH:模型对照组0.74±0.07mg/g,THH低剂量治疗组0.89±0.20mg/g,THH高剂量治疗组1.04±0.13mg/g,空白对照组0.89±0.25mg/g;CAT:模型对照组4.48±1.88U/mg,THH低剂量治疗组4.79±3.01U/mg,THH高剂量治疗组6.02±3.10U/mg,空白对照组3.47±1.43U/mg。),详见表3,表3是本发明THH治疗NAFLD大鼠后大鼠血清氧化能力SOD、MDA、GSH、CAT的因子变化结果;
表3 THH对NAFLD大鼠氧化应激指标的影响
实施例5
THH对NAFLD大鼠的炎性因子影响的研究。
实验中所采用的动物和实验药品和实施例2相同
大鼠IL-1、IL-6、TNF-α等炎性因子的Elisa试剂盒购于Bio-Swamp公司。
实验中大鼠造模和治疗和实施例2中所采用的方法相同。
用相应试剂盒检测大鼠血清IL-1、IL-6、TNF-α3个指标。发现PHA治疗组与模型组相比,3个指标均有明显好转(IL-6:模型对照组86.39±11.87pg/mL,THH低剂量治疗组52.68±9.24pg/mL,THH高剂量治疗组48.26±8.14pg/mL,空白对照组47.86±6.41pg/mL;IL-1α:模型对照组177.16±0.22ng/mL,THH低剂量治疗组157.62±0.11ng/mL,THH高剂量治疗组143.44±0.12ng/mL,空白对照组135.41±0.07ng/mL;TNF-α:模型对照组76.44±0.27ng/mL,THH低剂量治疗组68.81±0.24ng/mL,THH高剂量治疗组61.79±0.16ng/mL,空白对照组57.69±0.14ng/mL),提示THH可以明显的降低NAFLD大鼠机体炎性反应,经检验治疗后3个组p值均小于0.05。详见表4,表4是本发明THH治疗NAFLD大鼠后大鼠血清中的大鼠部分炎性因子IL-1、IL-6和TNF-α的变化。
表4THH对NAFLD大鼠血清炎性因子指标的影响
以上公开的本发明优选实施例只是用于帮助阐述本发明。优选实施例并没有详尽叙述所有的细节,也不限制该发明仅为所述的具体实施方式。显然,根据本说明书的内容,可作很多的修改和变化。本说明书选取并具体描述这些实施例,是为了更好地解释本发明的原理和实际应用,从而使所属技术领域技术人员能很好地理解和利用本发明。本发明仅受权利要求书及其全部范围和等效物的限制。
Claims (6)
1.山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用。
2.如权利要求1所述的应用,其特征在于:山海棠素对肝小叶和肝索结构破坏的恢复具有促进恢复作用。
3.如权利要求2所述的应用,其特征在于:促进恢复作用具体包括:血清肝功能、血脂和肝脂、肝脏和血清炎性因子水平的提高,SOD、MDA、GSH、CAT氧化和抗氧化能力的提高。
4.如权利要求1所述的应用,其特征在于:所述药物包含有效剂量的山海棠素THH和制药学上可接受的药物辅剂。
5.如权利要求4所述的应用,其特征在于:所述有效剂量为0-420mM。
6.如权利要求4所述的应用,其特征在于:所述药物为为内用药物,包括但不限于胶囊剂、丸剂、粉剂、片剂、粒剂、口服液或注射液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311429532.2A CN117323337A (zh) | 2023-10-31 | 2023-10-31 | 山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311429532.2A CN117323337A (zh) | 2023-10-31 | 2023-10-31 | 山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117323337A true CN117323337A (zh) | 2024-01-02 |
Family
ID=89293153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311429532.2A Withdrawn CN117323337A (zh) | 2023-10-31 | 2023-10-31 | 山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117323337A (zh) |
-
2023
- 2023-10-31 CN CN202311429532.2A patent/CN117323337A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Diwanay et al. | Immunoprotection by botanical drugs in cancer chemotherapy | |
CN105920018B (zh) | 雷公藤红素联合小檗碱制备治疗肥胖药物的用途 | |
JP4346685B2 (ja) | パルテニウム・インテグリフォリウム又はその部分若しくはそのエキス又はその成分を含有する医薬組成物、かかる植物材料の医薬製造のための使用、及びパルテニウム・インテグリフォリウムのエキスの製造方法 | |
CN106336445A (zh) | 化合物20(R)‑人参皂苷Rg3的制备方法及应用 | |
Guo et al. | The traditional uses, phytochemistry, pharmacokinetics, pharmacology, toxicity, and applications of Corydalis saxicola bunting: A review | |
Kim et al. | Heat-processed ginseng saponin ameliorates the adenine-induced renal failure in rats | |
KR20000061327A (ko) | 간질환 예방 및 치료용 생약조성물 | |
CN101254186A (zh) | 一种杨梅素的医药新用途 | |
CN117323337A (zh) | 山海棠素在制备治疗非酒精性脂肪性肝病药物中的应用 | |
CN107412243B (zh) | 一种预防或治疗脂肪肝的药物及其应用 | |
CN113209182B (zh) | 一种用于治疗类风湿关节炎的中药组合物及其制备方法 | |
CN102579528B (zh) | 一种防治前列腺疾病的药物组合物 | |
CN100406026C (zh) | 一种治疗慢性胃炎、胃癌的药物及其制备方法 | |
CN102940621B (zh) | 甲基阿魏酸在制备预防和治疗肝纤维化药物中的应用 | |
CN102772406A (zh) | 氧化苦参碱治疗银屑病的新的用途方法 | |
CN105497167A (zh) | 猫爪草在制备治疗和/或预防溃疡性结肠炎药物方面的新用途 | |
WO2018228431A1 (zh) | 升麻三萜皂苷类提取物、黄肉楠碱、脱氧升麻烃的用途 | |
CN116265027B (zh) | 一种治疗炎症性皮肤病的含雷公藤属药材的中药复方制剂 | |
CN110882254A (zh) | 一种治疗急性胃炎的组合物及其应用 | |
CN113440584B (zh) | 用于非酒精性脂肪肝治疗的中药组合物 | |
CN111297887B (zh) | 一种白云参保肝活性组分的制备方法及用途 | |
CN114469972B (zh) | 白头翁皂苷b4和/或白头翁皂苷b5在制备预防或治疗药物性肝损伤药物中的应用 | |
CN116077610B (zh) | 缓解酒精性肝损伤的中药组合物、其制备方法及其应用 | |
CN116270616A (zh) | Carquinostatin A化合物在制备治疗炎症性肠病的药物中的应用 | |
CN1569085A (zh) | 一种治疗风湿类风湿性关节炎的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20240102 |